- Home
- RFL vs RNXT Comparison
RFL vs RNXT Comparison
Compare RFL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- RNXT
- Stock Information
- Founded
- RFL 2017
- RNXT 2012
- Country
- RFL United States
- RNXT United States
- Employees
- RFL N/A
- RNXT N/A
- Industry
- RFL Real Estate
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- RNXT Health Care
- Exchange
- RFL Nasdaq
- RNXT Nasdaq
- Market Cap
- RFL 54.4M
- RNXT 44.6M
- IPO Year
- RFL N/A
- RNXT 2021
- Fundamental
- Price
- RFL $1.44
- RNXT $0.87
- Analyst Decision
- RFL
- RNXT Strong Buy
- Analyst Count
- RFL 0
- RNXT 2
- Target Price
- RFL N/A
- RNXT $7.25
- AVG Volume (30 Days)
- RFL 58.4K
- RNXT 218.3K
- Earning Date
- RFL 06-11-2025
- RNXT 08-14-2025
- Dividend Yield
- RFL N/A
- RNXT N/A
- EPS Growth
- RFL N/A
- RNXT N/A
- EPS
- RFL N/A
- RNXT N/A
- Revenue
- RFL $732,000.00
- RNXT $662,000.00
- Revenue This Year
- RFL N/A
- RNXT $3,104.65
- Revenue Next Year
- RFL N/A
- RNXT $301.89
- P/E Ratio
- RFL N/A
- RNXT N/A
- Revenue Growth
- RFL 35.56
- RNXT N/A
- 52 Week Low
- RFL $1.28
- RNXT $0.75
- 52 Week High
- RFL $3.19
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- RFL 31.57
- RNXT 26.17
- Support Level
- RFL $1.66
- RNXT $1.23
- Resistance Level
- RFL $1.67
- RNXT $1.37
- Average True Range (ATR)
- RFL 0.09
- RNXT 0.10
- MACD
- RFL -0.03
- RNXT -0.03
- Stochastic Oscillator
- RFL 0.00
- RNXT 12.28
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.